Results of a randomized, placebo-controlled trial of sulindac in the reduction of colonic polyps in Familial Adenomatous Polyposis (FAP) (more details available below the variable definitions).
polypsA data frame with 22 observations and 7 variables
id number for each participant; type: character
participant sex, levels: female, male; type: factor
age in years; type: numeric
number of colonic polyps at baseline; type: numeric
treatment assignment, levels: sulindac, placebo; type: factor
number of colonic polyps at 3 months; type: numeric
number of colonic polyps at 12 months; type: numeric
FAP is an inherited condition caused by mutations in the APC (Adenomatous Polyposis Coli) gene that leads to early and frequent formation of precancerous polyps of the colon at a young age, and invariably leads to the development of colon cancer at a young age. Early, frequent surveillance colonoscopy and polyp removal is helpful, but this study examined whether there is a beneficial effect of preventive medical therapy with the nonsteroidal pain reliever, sulindac, versus placebo in a RCT vs placebo in 22 participants, with polyp number measured (via colonoscopy) at baseline, 3 months, and 12 months after starting the study drug. Note that one subject did not return for the 12 month colonoscopy.